Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)

W. W. Tan, D. W. Hillman, M. Salim, D. W. Northfelt, D. M. Anderson, P. J. Stella, R. Niedringhaus, A. M. Bernath, S. S. Gamini, F. Palmieri, E. A. Perez

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

The following funding statement was missing from the original manuscript: ‘Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.’ This has now been amended in the online version.

Original languageEnglish (US)
Pages (from-to)493-497
Number of pages5
JournalAnnals of Oncology
Volume29
Issue number10
DOIs
StatePublished - Jan 1 2018

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this